A Study of RAY1225 in Participants With Type 2 Diabetes

Phase 2

Recruiting

• Conditions: T2DM (Type 2 Diabetes Mellitus)
• Interventions: Drug: Placebo; Drug: RAY1225

• Registration Number: NCT06254274
• Lead Sponsor: Guangdong Raynovent Biotech Co., Ltd

Brief Summary

The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with type 2 diabetes mellitus. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-02-03
• Study First Submitted QC: 2024-02-03
• Study First Posted: 2024-02-12
• Study Start: 2024-02-26
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-04
• Last Update Posted: 2025-03-05
• Primary Completion: 2025-12-20
• Study Completion: 2025-12-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 270

Inclusion Criteria

1. Type 2 diabetes had been diagnosed for at least 12 weeks prior to screening and one of the following conditions:

   1. have T2DM controlled with diet and exercise alone;
   2. are stable in dose and type on a single or in a combination of oral antidiabetic medication, metformin, α-glucosidase inhibitors or SGLT-2 inhibitors only ,within 12 weeks before screening;

2. BMI ≥ 20 kg/m²；

3. Fasting blood-glucose（FPG）<15 mmol/L;

4. Weight change < 5% in the 12 weeks before screening;

5. Participants (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product.

Exclusion Criteria

1. have type 1 diabetes mellitus；
2. Severe diabetic complications, including proliferative retinopathy or maculopathy, severe diabetic neuropathy (e.g., urinary retention, urinary incontinence, and painful peripheral neuropathy), resting tachycardia, orthostatic hypotension, intermittent claudication, or diabetic foot;
3. Two or more episodes of ketoacidosis, lactic acidosis, or hyperosmolar state leading to hospitalization within 24 weeks before screening;
4. had grade 3 hypoglycemic events within 12 months before screening,
5. Three or more grade 2 hypoglycemic events occurred within 3 months before screening;
6. Have symptoms related to hypoglycemia at screening;
7. Within 6 weeks before screening, serious trauma, serious infection, or surgery that may have affected glycemic control was reported;
8. Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2 or with thyroid nodules of unknown etiology found at screening and considered clinically significant by the investigator.
9. Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed >1 year prior to screening)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo (cohort 1)	Placebo	Participants received Placebo administered SC once two weeks for 24 weeks.
Placebo (cohort 2)	Placebo	Participants received Placebo administered SC once two week
RAY1225 (cohort 2)	RAY1225	Escalating doses of RAY1225 administered subcutaneously (SC) once two week
RAY1225 (cohort 1)	RAY1225	Participants received dose1 or dose2 RAY1225 administered subcutaneously (SC) once two week for 24 weeks.

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Hemoglobin A1c (HbA1c)	Baseline,Week 26	HbA1c is the glycosylated fraction of hemoglobin A.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With HbA1c Target Value of <6.5%	Baseline,Week26
Percentage of Participants With HbA1c Target Value of <7%	Baseline,Week26
Percentage of Participants With HbA1c Target Value of <5.7%	Baseline,Week26
Change From Baseline in Fasting Serum Glucose	Baseline,Week26

Trial Locations

Locations (1)

Peking University People's Hospital; 🇨🇳 Beijing, Hebei, China